American Society of Hirudotherapy

Updates on Use and Monitoring of Direct Thrombin Inhibitors

Review published in Clin Lab Med (2026)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDrug DevelopmentSalivary PharmacologyNavaei A et al. · Clinics in laboratory medicine, 2026

Abstract

Direct thrombin inhibitors (DTIs) such as bivalirudin and argatroban have a predictable anticoagulant response, the ability to inhibit thrombin bound to fibrin, and efficacy in thrombotic environments. These properties make them a valuable tool to manage patients at risk of thrombotic events. DTIs require less frequent monitoring and dose adjustments than heparin. Due to poor correlation of activated partial thromboplastin time with DTI concentration, diluted thrombin time is widely used for monitoring bivalirudin anticoagulation. Emerging monitoring methods are promising and reflect the evolution of precision medicine toward more personalized, real-time monitoring techniques that can guide anticoagulation therapy in complex cases.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansAntithrombinsDrug MonitoringHirudinsBlood Coagulation TestsPipecolic AcidsThrombinRecombinant ProteinsPeptide FragmentsArginineSulfonamides

Summary

Up-to-date review of the clinical use and laboratory monitoring of direct thrombin inhibitors — including bivalirudin, argatroban, and dabigatran — which descended from leech hirudin, with attention to coagulation assay interpretation and dose adjustment.

Why This Matters for Hirudotherapy

This article discusses the clinical use and monitoring of direct thrombin inhibitors (DTIs) such as bivalirudin and argatroban, describing their properties—including predictable anticoagulant response and the ability to inhibit fibrin-bound thrombin—and current and emerging monitoring methods such as diluted thrombin time. This work is relevant to hirudotherapy because bivalirudin is a synthetic analog of hirudin, the potent antithrombin originally identified in medicinal leech saliva, meaning that advances in DTI monitoring and dosing strategies directly inform the clinical understanding and therapeutic application of leech-secretome-derived anticoagulants in thrombotic settings. A caveat is that the abstract focuses on monitoring approaches and general pharmacological properties rather than presenting new primary clinical trial data, and it addresses pharmaceutical DTI management rather than live leech therapy itself.

Citation

Updates on Use and Monitoring of Direct Thrombin Inhibitors.

Navaei A et al. · Clinics in laboratory medicine, 2026

DOI

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.